Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IOV-001
- Development stage
- Unknown
- Lead developer
- Imvax
- Modality
- Cell Therapies, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Implantation
01
Overview
**IOV-001** is an experimental, personalized autologous whole tumor-derived cancer immunotherapy from Imvax being developed for ovarian cancer. It belongs to the company's Goldspire platform, which combines irradiated patient-derived tumor cells with the antisense oligodeoxynucleotide IMV-001 directed against insulin-like growth factor 1 receptor and places the treated cells in biodiffusion chambers intended to release tumor antigens and immune-stimulating signals while preventing viable tumor-cell escape. Publicly available information indicates that ovarian-cancer versions of this platform have shown preclinical antitumor activity in murine ovarian cancer models, but there is no clear evidence of approved use or established human clinical development for this specific ovarian product candidate.
- Other names
- IOC-001IOC001IOC 001
Beyond the preview
Go deeper on IOV-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IOV-001.